EORTC 22996-24002/TROG 01.01 - EPO Head & Neck

By w.paterson
14 August, 2021
0 Comments

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

24 June, 2025

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

TROG 2024 Annual Research Report highlights a year of achievements

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

TROG 2024 Annual Research Report highlights a year of achievements

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer